Ob/Gyn Medical News about Sumatriptan Pregnancy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?
Headache: The Journal of Head and Face Pain, 10/07/09

Cunnington M et al. – The risk of all major birth defects following first–trimester exposure to sumatriptan was 4.6% (95% CI 2.9–7.2%). This coupled with a consistent failure of additional epidemiological studies to observe a signal for major teratogenicity gives a level of reassurance concerning the safety of sumatriptan in pregnancy. There are too few data on naratriptan to draw definitive conclusions, and the sample size for sumatriptan remains too small to detect any but very large increases in specific birth defects.

<< Previous
CCHIT Revamping EHR Certification

Next >>
Fertility Preservation: Definition, History, and Prospect

Embryonic development and pregnancy test sensitivity: the importance of earlier pregnancy detection
Women's Health, 11/04/09 Relevance Score: 48%

Trauma in Pregnancy
American Journal of Nursing, 11/10/09 Relevance Score: 46%

Medical treatments for idiopathic thrombocytopenic purpura during pregnancy
Cochrane Reviews, 10/27/09 Relevance Score: 46%

Sexuality During Pregnancy
The Journal of Sexual Medicine, 10/23/09 Relevance Score: 46%

Routine pre-pregnancy health promotion for improving pregnancy outcomes
Cochrane Reviews, 10/22/09 Relevance Score: 46%